Financial Data and Key Metrics Changes - The company reported fourth quarter revenue of $198 million, representing an 18% year-over-year increase and 14% organic growth, exceeding guidance [6][24] - For the full year, revenue grew 16% on both a reported and organic non-COVID basis, with full year organic growth of 14% [7][24] - Adjusted operating margin for the fourth quarter was 15%, reflecting a 10 basis point increase year-over-year, and 240 basis points expansion excluding M&A and foreign currency impacts [27][28] Business Line Data and Key Metrics Changes - Proteins and process analytics both grew over 30% in the fourth quarter, while chromatography grew more than 25% [7][19] - Filtration revenue grew high single digits for both the quarter and the year, driven by consumables [8][18] - New modalities grew low single digits for the year, with strength in cell therapy but headwinds in mRNA demand [11][12] Market Data and Key Metrics Changes - North America represented approximately 47% of total revenue, growing mid-teens, while EMEA grew more than 20% [25] - Asia Pacific grew high teens, driven by chromatography and analytics, with China showing signs of recovery [25] - Biopharma revenue grew over 20% year-over-year, with strong growth from both pharma and emerging biotech [11] Company Strategy and Development Direction - The company aims to outpace bioprocessing industry growth, drive operating leverage, and continue innovation through new product launches [22][23] - Focus on integrating recent acquisitions and pursuing additional M&A opportunities remains a priority [16][23] - The company is committed to margin expansion while balancing investments for future growth, with a target of 150 basis points operating margin expansion in 2026 [10][34] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about a strengthening macro backdrop, including improved biotech funding and positive pharma sentiment [10] - The guidance for 2026 is set at $810 million-$840 million, reflecting a 9%-13% organic revenue growth expectation [9][32] - Management acknowledged potential headwinds from FDA policy and biopharma's strategic responses to market changes [10][11] Other Important Information - The company has a strong cash position of $768 million at the end of the fourth quarter, up $90 million sequentially [30][38] - Adjusted fully diluted earnings per share for the fourth quarter was $0.49, compared to $0.44 in the same period in 2024 [30] - The company plans to continue investing in IT modernization and leadership development to support growth [17][34] Q&A Session Summary Question: Can you provide insights on the guidance and customer confidence regarding the policy environment? - Management noted that tariffs remain an open question but do not significantly impact total sales, and there is a strong funnel of opportunities with high probability [40][42][44] Question: How does margin expansion rank relative to M&A priorities? - Management emphasized that margin expansion remains a top priority alongside above-market growth, with a balanced approach to potential acquisitions [47][49] Question: What assumptions are made regarding pacing and market normalization? - Management indicated that while there are strong opportunities, macro factors could influence CapEx spending decisions, leading to a cautious approach in guidance [56][58][59] Question: Can you clarify the organic growth expectations for Q1 and the year? - Management expects Q1 to be only slightly down sequentially from Q4, indicating a strong start to the year, with a focus on translating opportunities into orders [63][64] Question: What is the outlook for the analytics portfolio growth? - Management expressed confidence in achieving above 20% growth in analytics, driven by the ongoing upgrade cycle of the SoloVPE PLUS System and the expanded product portfolio from recent acquisitions [82][84]

Financial Data and Key Metrics Changes - For the full year 2025, sales reached $24.6 billion, with core revenue increasing by 2% [9] - Adjusted operating profit margin was 28.2%, and adjusted diluted net earnings per common share were $7.80, up 4.5% year-over-year [9] - Free cash flow generated was $5.3 billion, resulting in a free cash flow to net income conversion ratio of approximately 145% [10] Business Line Data and Key Metrics Changes - Biotechnology segment core revenue increased by 6% [16] - Bioprocessing core revenue grew high single digits, with consumables and equipment both contributing to growth [16] - Life sciences segment core revenue increased by 0.5%, with consumables experiencing a decline due to lower demand [19] - Diagnostics segment core revenue increased by 2%, with clinical diagnostics growing mid-single digits [20] Market Data and Key Metrics Changes - Core revenues in developed markets increased low single digits, with North America flat and Western Europe up mid-single digits [15] - High growth markets saw mid-single digit increases, with solid growth outside of China, offsetting a low single-digit decline in China [15] Company Strategy and Development Direction - The company aims for long-term value creation through a differentiated portfolio and the Danaher Business System [9] - Continued investments in innovation led to over 20 new product launches in biotechnology, enhancing customer capabilities [10] - The company anticipates high single-digit core revenue growth in bioprocessing for 2026, driven by strong underlying biologic demand [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about gradual end market improvements continuing into 2026, particularly in bioprocessing and diagnostics [9][23] - The company expects core revenue growth in the range of 3%-6% for 2026, with adjusted diluted EPS guidance set at $8.35-$8.50 [23] Other Important Information - The company has maintained a free cash flow to net income conversion ratio exceeding 100% for 34 consecutive years [10] - The FDA approved several new products, including Cepheid's Xpert GI Panel, enhancing the company's diagnostic capabilities [12] Q&A Session Summary Question: Insights on core revenue guidance - Management indicated that the 3%-6% core revenue guidance reflects expectations of continued recovery in end markets, particularly in bioprocessing and diagnostics [31][33] Question: Bioprocessing order book and growth outlook - The order book supports high single-digit growth for bioprocessing, with consumables expected to perform well [36][105] Question: Strength in SCIEX and end market recovery - SCIEX experienced mid-single-digit growth, driven by innovation and improvements in the pharma end market [42] Question: Margin expectations for 2026 - Management expects low single-digit core growth to translate into margin improvements, with benefits from cost actions contributing to earnings [44][78] Question: Biotech funding environment impact - The biotech segment is sensitive to funding improvements, which could enhance order volumes in the future [95][96]